Cardeas Pharma Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Out of Business

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Out of Business

Cardeas Pharma General Information

Description

Developer of inhaled antibiotics created to treat respiratory infections caused by antibiotic-resistant organisms. The company specializes in early phase development of inhaled antibiotics to treat serious, hospital-acquired respiratory infections with highly antibiotic-resistant organisms and combines formations of antibiotics of two drugs with drug-delivery technology to address resistant gram-negative bacteria, enabling patients to met medical needs in the critical care setting.

Contact Information

Website
www.cardeaspharma.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 2025 First Avenue
  • Suite 1200
  • Seattle, WA 98121
  • United States
+1 (206)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Corporate Office
  • 2025 First Avenue
  • Suite 1200
  • Seattle, WA 98121
  • United States
+1 (206)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cardeas Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Out of Business 01-Dec-2017 Completed Out of Business
5. Early Stage VC (Series B) 09-Apr-2015 Completed Startup
4. Early Stage VC (Series B) 22-May-2013 Completed Startup
3. Early Stage VC (Series A) 26-Sep-2012 Completed Startup
2. Early Stage VC 18-Feb-2011 $1M $1.02M Completed Startup
1. Seed Round 10-Aug-2010 $20.1K $20.1K Completed Startup
To view Cardeas Pharma’s complete valuation and funding history, request access »

Cardeas Pharma Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A
To view Cardeas Pharma’s complete cap table history, request access »

Cardeas Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of inhaled antibiotics created to treat respiratory infections caused by antibiotic-resistant organisms. The c
Biotechnology
Seattle, WA
2 As of 2016

Cambridge, MA
 

Stockholm, Sweden
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cardeas Pharma Competitors (14)

One of Cardeas Pharma’s 14 competitors is Avalyn Pharma, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avalyn Pharma Venture Capital-Backed Cambridge, MA
Gesynta Pharma Venture Capital-Backed Stockholm, Sweden
Ona Therapeutics Venture Capital-Backed Barcelona, Spain
Lung Therapeutics Formerly VC-backed Austin, TX
Cardurion Venture Capital-Backed Burlington, MA
You’re viewing 5 of 14 competitors. Get the full list »

Cardeas Pharma Patents

  • 7

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 2

    Pending

  • Expiring in next 12 mo

Cardeas Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2014311282-A1 Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties Inactive 26-Aug-2013
JP-2016534122-A Aminoglycoside and fosfomycin combination formulation with improved chemical properties Pending 26-Aug-2013
EP-3038599-A1 Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties Inactive 26-Aug-2013
CA-2922337-A1 Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties Inactive 26-Aug-2013
AU-2012281068-A1 Formulations of amikacin and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis Inactive 12-Jul-2011 A61K31/7036
To view Cardeas Pharma’s complete patent history, request access »

Cardeas Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Cardeas Pharma FAQs

  • When was Cardeas Pharma founded?

    Cardeas Pharma was founded in 2010.

  • Where is Cardeas Pharma headquartered?

    Cardeas Pharma is headquartered in Seattle, WA.

  • What is the size of Cardeas Pharma?

    Cardeas Pharma has 2 total employees.

  • What industry is Cardeas Pharma in?

    Cardeas Pharma’s primary industry is Biotechnology.

  • Is Cardeas Pharma a private or public company?

    Cardeas Pharma is a Private company.

  • What is Cardeas Pharma’s current revenue?

    The current revenue for Cardeas Pharma is .

  • How much funding has Cardeas Pharma raised over time?

    Cardeas Pharma has raised $53.6M.

  • Who are Cardeas Pharma’s competitors?

    Avalyn Pharma, Gesynta Pharma, Ona Therapeutics, Lung Therapeutics, and Cardurion are some of the 14 competitors of Cardeas Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »